Eklund 1986.
Methods | Double blind RCT Concealment of allocation ‐ unclear Endpoint analysis Active treatment 4 weeks | |
Participants | Inclusion criteria: 17+ HMDR primary illness Age: 60‐80 Country:Sweden /Netherlands Setting: unclear | |
Interventions | Mianserin versus Imipramine | |
Outcomes | Side effects Drop out HMD(21 item) | |
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |